Effect of Silencing LRIG3 Gene on the Proliferation and Apoptosis of Bladder Cancer T24 Cells

This study examined the effect of silencing LRIG3 expression on the proliferation and apoptosis of bladder cancer T24 cells and explored the role of LRIG3 in the tumorigenesis of bladder cancer. Bladder cancer T24 cells were routinely cultured and pSilencer plasmids were employed to construct LRIG3 eukaryotic expression vector of LRIG3-siRNA, i.e., pSilencer-LRIG3-siRNA. After confirmation, the vector was transfected into HEK293 cells to make a replication-deficient adenovirus, pAd-LRIG3-siRNA, which was then introduced into bladder cancer T24 cells. RT-PCR, Western- blotting were performed to detect the levels of LRIG3 mRNA and proteins. Cells number was determined by using MTT test. Hoechst33258 staining, transmission microscopy, flow cytometery were conducted to examine the cell apoptosis. Three groups included a blank control group, a negative control group （containing non-interfering plasmids） and a pAd-LRIG3-siRNA group. Our results showed that the recombinant pAd-LRIG3-siRNA was successfully transfected into the bladder cancer T24 cells. The siRNA formed by the transcription of the recombinant plasmids resulted in significantly reduced expressions of LRIG3 gene and protein and significantly decreased cell proliferation and growth in the pAd-LRIG3-siRNA group as compared with the control group （P0.01）. The siRNA also caused apoptotic changes of some cells, with the apoptosis rate being （17.69±0.75）%, which was significantly different from that of the control group （P0.01）. It was concluded that recombinant pAd-LRIG3-siRNA plasmids could effectively decrease the expression of LRIG3 mRNA and proteins and, to some extent, inhibit the proliferation and promote the apoptosis of bladder cancer T24 cells. Silencing LRIG3 gene might be a novel alternative for the treatment of bladder cancer.

LRIG3特异性RNA干扰真核表达载体的构建及稳定株筛选

目的构建LRIG3(leucine-rich repeats and immunoglobulin-like domains 3,LRIG3)基因特异的RNA干扰质粒,为探讨抑制LRIG3基因表达对脑胶质瘤细胞生物学行为调控的研究奠定基础。方法根据GenBank数据库提供的LRIG3基因核苷酸序列,选择设计2条能转录短发卡RNA(shRNA)的DNA序列,命名为LRIG3-shRNA1、LRIG3-shRNA2,同时设计1条非特异性序列作为阴性对照,命名为negative-shRNA。并与pGenesil2质粒载体连接,转化感受态大肠杆菌,挑选阳性克隆,抽取重组质粒,使用限制性内切酶SalI酶切电泳,DNA测序鉴定。3种重组表达载体转染胶质瘤细胞系GL15细胞,用G418筛选后挑选单克隆并扩增获得稳定株。逆转录酶-聚合酶链反应(RT-PCR)和Western blot分别在mRNA和蛋白水平上检测LRIG3的表达。结果重组质粒成功转化感受态大肠杆菌,经SalI酶切琼脂糖凝胶电泳分析,结果表明寡核苷酸成功插入到预计位点,经测序鉴定,序列完全正确。G418筛选出稳定转染三种质粒的GL15细胞,转染pGenesil2-LRIG3-shRNA组细胞LRIG3mRNA和蛋白表达明显低于转染pGenesil2-negative-shRNA组。结论成功构建针对LRIG3基因的特异性shRNA真核表达载体,转染细胞后可抑制LRIG3基因表达,为进一步研究其基因功能奠定了基础。

LRIG3基因特异性siRNA腺病毒表达载体的构建与鉴定

目的构建并鉴定针对LRIG3基因的小干扰RNA(LRIG3-siRNA)腺病毒表达载体,为膀胱癌基因治疗的研究提供有效的实验工具。方法设计可形成小发夹结构的LRIG3-siRNA模板cDNA序列,克隆至缺陷型腺病毒质粒pSilencer-U6neo,构建LRIG3-siRNA表达质粒pSilencer-LRIG3。鉴定正确后,将pSilencer-LRIG3转染至HEK293细胞,包装成复制缺陷型腺病毒pAd-LRIG3。大量扩增pAd-LRIG3,氯化铯梯度离心纯化,测病毒滴度。pAd-LRIG3感染人膀胱癌细胞T24,RT-PCR法检测LRIG3 mRNA的表达。结果酶切分析、测序鉴定表明pSilencer-LRIG3构建成功,PCR分析表明pAd-LRIG3含有LRIG3-siRNA序列。pAd-LRIG3可抑制LRIG3 mRNA的表达。结论含有LRIG3-siRNA的重组腺病毒构建成功,且具有抑制LRIG3基因mRNA表达的功能。

膀胱尿路上皮癌中LRIG3基因的表达及其临床意义

目的:探讨富含亮氨酸重复序列和免疫球蛋白样多肽3(LRIG3)基因与膀胱尿路上皮癌(BUC)生物学行为的关系。方法:采用免疫组织化学SP法和逆转录-聚合酶链反应(RT-PCR)法检测64例膀胱尿路上皮癌组织和12例正常膀胱黏膜中LRIG3蛋白及mRNA的表达情况,并结合临床资料进行分析。结果:膀胱癌组织中LRIG3蛋白和mRNA的表达水平显著低于正常膀胱黏膜组织,且分级和分期越高,LRIG3蛋白和mRNA的表达水平越低。结论:LRIG3基因在膀胱癌组织中存在表达缺失和低表达,提示LRIG3基因在膀胱癌的发生发展中可能具有抑癌基因的作用,有可能成为肿瘤基因治疗的又一靶点。